ADXS31-142
- Generic Name
- ADXS31-142
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- First Posted Date
- 2014-12-25
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Advaxis, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT02325557
- Locations
- 🇺🇸
Recruiting, Providence, Rhode Island, United States
🇺🇸Recrutiing, Philadelphia, Pennsylvania, United States
🇺🇸University of Colorado Health Sciences Center (UCHSC), Aurora, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath